Navigation Links
Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
Date:7/29/2008

actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; the results of clinical trials; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increased costs; the effect or outcome of the Company's decision to sell Estrasorb(R); the human capital and other costs Novavax will incur to exit the manufacturing facility; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to upda
'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax to Join Russell 3000 Index
2. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
3. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
4. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
5. Novavax Reports First Quarter 2008 Financial Results
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Opens Its First U.S. Vaccine Plant
8. Novavax CEO to Present at the World Vaccine Congress 2008
9. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
10. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
11. Novavax CEO to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --  ISN has released its third annual U.S. ... publication series. With data aggregated from over eight billion ... its online contractor management platform, ISNetworld, this three-part series ... statistics. The Contractor Performance ... available in two industry specific volumes: Oil & ...
(Date:12/17/2014)... The Activated Carbon Manufacturing industry ... IBISWorld updated its original industry research report. , ... intensified focus on environmental policy. Over the five years ... power plants and a range of other industrial facilities ... Sarah Kahn, “a range of downstream industrial sectors rely ...
(Date:12/17/2014)... Bellingham, Washington, USA (PRWEB) December 16, 2014 ... Kirstin Baum, manager at Philipps- Universität Marburg’s Department ... optics and photonics, in the newly released ... 2015-2016. “And never be too shy to ask ... STEM (science, technology, engineering, and mathematics) occupations ranging ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... 20 eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ), ... interpretation services,announced today that Dr. Michael J. McKelvey, ... Baron, the Company,s Chief Financial,Officer, are scheduled to ... at 9:00 a.m. Eastern on May 28, 2008 ...
... Parents of children with,autism often grapple with a bewildering ... the disorder? Could it be genetic? What is it,like to ... therapies that,might alleviate some of my child,s symptoms?", On ... will have a unique opportunity to hear from researchers on ...
... on Regenesis, SCOTTSDALE, Ariz., May 20 ... the Provant(R) Wound Therapy,System, announced today the formation ... to guide advanced scientific investigations into the,mechanism of ... of Regenesis, platform technology to clinical and industrial,applications., ...
Cached Biology Technology:eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008 2First Annual Autism Conference at Packard Children's and Stanford Brings Parents and Researchers Together 2First Annual Autism Conference at Packard Children's and Stanford Brings Parents and Researchers Together 3Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 2Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 3
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego ... that provides the connective tissue that enhances care coordination ... to easily share client-level information; earned a second $1 ... to organizations serving seniors aging in community and; will ... on December 11 th 4-6p. CIE ...
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... of us never considered eating the mud pies we made ... dining on dirt is nothing out of the ordinary. Now ... The Quarterly Review of Biology helps explain why. ... human geophagythe eating of earthis that it protects the stomach ...
... a researcher, please contact the Communications and External Relations staff member ... ORNL and its research and development activities, please refer to one ... or comment, you can send it to news@ornl.gov . ... Unsafe commercial motor vehicles may be off the ...
... like a computer. An organism,s genome is the software ... do. But instead of electronic circuitry, life relies on ... organisms to function. Now, researchers at the California Institute ... circuit ever created from scratch, made with DNA-based devices ...
Cached Biology News:Eating dirt can be good for the belly, researchers find 2Eating dirt can be good for the belly, researchers find 3Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2011 2Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 2Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 3Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 4
golgi reassembly stacking protein 2, 55kDa...
...
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Reactivity: Human...
Biology Products: